Patents by Inventor Masaki Ogino
Masaki Ogino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190083467Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.Type: ApplicationFiled: March 9, 2017Publication date: March 21, 2019Inventors: Masaki OGINO, Eiji KIMURA, Shinkichi SUZUKI, Kouji FUJI, Tomohiro OHASHI, Makoto FUSHIMI, Kei MASUDA, Tatsuki KOIKE, Takeshi WAKABAYASHI, Jinichi YONEMORI, Masami YAMADA
-
Patent number: 10214508Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.Type: GrantFiled: June 11, 2015Date of Patent: February 26, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Tomoko Ashizawa, Toshihiro Imaeda, Ikuo Fujimori, Ryosuke Arai
-
Patent number: 10202376Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.Type: GrantFiled: December 21, 2015Date of Patent: February 12, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Eiji Kimura, Yuhei Miyanohana, Masaki Ogino, Yuta Tanaka, Makoto Fushimi, Tomohiro Okawa, Yuki Hanya, Tatsuki Koike
-
Publication number: 20190040010Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: August 2, 2018Publication date: February 7, 2019Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuichi Kajita, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OHYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
-
Publication number: 20180303841Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.Type: ApplicationFiled: October 19, 2016Publication date: October 25, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Takuto KOJIMA, Jinichi YONEMORI
-
Publication number: 20180162850Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: June 23, 2016Publication date: June 14, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
-
Publication number: 20170362223Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.Type: ApplicationFiled: December 21, 2015Publication date: December 21, 2017Applicant: Takeda Pharmaceutical Company LimitedInventors: Eiji KIMURA, Yuhei MIYANOHANA, Masaki OGINO, Yuta TANAKA, Makoto FUSHIMI, Tomohiro OKAWA, Yuki HANYA, Tatsuki KOIKE
-
Publication number: 20170121308Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.Type: ApplicationFiled: June 11, 2015Publication date: May 4, 2017Inventors: Masaki OGINO, Eiji KIMURA, Shinkichi SUZUKI, Tomoko ASHIZAWA, Toshihiro IMAEDA, Ikuo FUJIMORI, Ryosuke ARAI
-
Patent number: 9605000Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.Type: GrantFiled: March 13, 2014Date of Patent: March 28, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Shizuo Kasai, Masaki Ogino, Ryo Mizojiri, Takeshi Yamasaki, Hideki Hirose, Nobuyuki Takakura, Tohru Yamashita, Sachie Morimoto, Takashi Nakahata, Asato Kina
-
Publication number: 20160376244Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: June 23, 2016Publication date: December 29, 2016Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
-
Publication number: 20160060273Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.Type: ApplicationFiled: March 13, 2014Publication date: March 3, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Shizuo KASAI, Masaki OGINO, Ryo MIZOJIRI, Takeshi YAMASAKI, Hideki HIROSE, Nobuyuki TAKAKURA, Tohru YAMASHITA, Sachie MORIMOTO, Takashi NAKAHATA, Asato KINA
-
Publication number: 20150299188Abstract: Provided is a compound having a superior FLAP inhibitory action and useful as a prophylactic or therapeutic agent for arteriosclerosis and the like, and a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present DESCRIPTION, or a salt thereof.Type: ApplicationFiled: August 23, 2013Publication date: October 22, 2015Inventors: Masaki OGINO, Zenichi IKEDA, Jun FUJIMOTO, Yusuke OHBA, Naoki ISHII, Takuya FUJIMOTO, Tsuneo ODA, Naohiro TAYA, Toshiro YAMASHITA, Nobuyuki MATSUNAGA
-
Patent number: 8786768Abstract: An image capturing device 100 includes three blocks, that is, a lens block 1 having an imaging lens 4, a display block 2, and a frame block 3. The display block 2 has a display unit 5 which performs display using a liquid crystal, a transparent touch screen 63 with which the display unit 5 is covered, a shutter button 61 which is disposed adjacent to the display unit 5, and a power button 62. The frame block 3 has a generally U-shaped frame form and surrounds the circumferences of the lens block 1 and the display block 2. Each of the display block 2 and the frame block 3 is coupled to the lens block 1 rotatably via a biaxial hinge unit. Especially, the display block 2 and the frame block 3 are coupled to the lens block 1 rotatably via a first hinge and second hinges.Type: GrantFiled: December 21, 2011Date of Patent: July 22, 2014Assignee: Casio Computer Co., Ltd.Inventors: Masaki Ogino, Yosuke Nagayama, Susumu Kamiya, Akira Suzuki, Tomoyasu Kurokawa
-
Publication number: 20120169913Abstract: An image capturing device 100 includes three blocks, that is, a lens block 1 having an imaging lens 4, a display block 2, and a frame block 3. The display block 2 has a display unit 5 which performs display using a liquid crystal, a transparent touch screen 63 with which the display unit 5 is covered, a shutter button 61 which is disposed adjacent to the display unit 5, and a power button 62. The frame block 3 has a generally U-shaped frame form and surrounds the circumferences of the lens block 1 and the display block 2. Each of the display block 2 and the frame block 3 is coupled to the lens block 1 rotatably via a biaxial hinge unit. Especially, the display block 2 and the frame block 3 are coupled to the lens block 1 rotatably via a first hinge and second hinges.Type: ApplicationFiled: December 21, 2011Publication date: July 5, 2012Applicant: Casio Computer Co., Ltd.Inventors: Masaki OGINO, Yosuke NAGAYAMA, Susumu KAMIYA, Akira SUZUKI, Tomoyasu KUROKAWA
-
Patent number: 7541478Abstract: The present invention relates to an alkaline earth metal salt or an organic amine salt of a compound represented by the formula [I]: wherein R1 and R2 are each a hydrogen atom, a halogen atom, or an optionally substituted linear hydrocarbon group; ring A is an optionally further substituted benzene ring; B is an optionally substituted benzene ring; R is a carboxyl group or a linear hydrocarbon group substituted with a carboxyl group and the like.Type: GrantFiled: March 1, 2005Date of Patent: June 2, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Shogo Marui, Masaki Ogino, Hiroyuki Tawada, Osamu Yabe
-
Publication number: 20090048258Abstract: The present invention relate to a compound represented by the formula (I) or (II) wherein ring A is an optionally substituted ring (the ring should not be pyrrolidine, piperidine and piperazine), ring B is an optionally substituted aromatic ring, ring D is an optionally substituted ring, R1 and R2 are each independently a hydrogen atom or a substituent, R3 is a hydrogen atom or a C1-6 alkyl group, or R3 is bonded to ring A to form a non-aromatic ring, ring Aa is an optionally substituted aromatic hydrocarbon, Y is CH or N, Ra1 is an optionally substituted hydrocarbon group, and Ra2 and Ra3 are each independently a hydrogen atom or a substituent, or a salt thereof. The present invention provides a compound having a DGAT inhibitory activity, which is useful for the treatment or amelioration of diseases or pathologies caused by high expression or high activation of DGAT.Type: ApplicationFiled: January 31, 2006Publication date: February 19, 2009Inventors: Masaki Ogino, Yoshihisa Nakada, Mitsuyuki Shimada, Kouhei Asano, Norikazu Tamura, Minori Masago
-
Patent number: D554681Type: GrantFiled: May 24, 2006Date of Patent: November 6, 2007Assignee: Casio Keisanki Kabushiki KaishaInventors: Masaki Ogino, Yosuke Nagayama
-
Patent number: D554684Type: GrantFiled: March 21, 2006Date of Patent: November 6, 2007Assignee: Casio Keisanki Kabushiki KaishaInventors: Masaki Ogino, Yosuke Nagayama
-
Patent number: D554691Type: GrantFiled: January 26, 2007Date of Patent: November 6, 2007Assignee: Casio Keisanki Kabushiki KaishaInventor: Masaki Ogino
-
Patent number: D636423Type: GrantFiled: September 15, 2010Date of Patent: April 19, 2011Assignee: Casio Keisanki Kabushiki KaishaInventors: Masaki Ogino, Susumu Kamiya, Yosuke Nagayama